arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 12/2018 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    New medical device regulation: a work of lobbyists

    THERAPY FROM A CRITICAL VIEWPOINT

    ODYSSEY OUTCOME trial: alirocumab after coronary syndrome

    REDUCE-IT trial: protection by fish oil or harm by mineral oil

    Stress ulcer prophylaxis with pantoprazole (PANTOZOL, generics): no effect on mortality

    Breast cancer: multigene test ONCOTYPE DX for therapeutic decision making

    CAR-T cells against cancer?

    IN BRIEF

    Finally – recommendation for lower dosage of colchicine

    Vitamin D – no protection against cancer and cardiovascular diseases

    CANEPHRON against uncomplicated cystitis?

    Nitrosamines in sartan drugs – the current situation

    a-t READERS QUESTIONS AND COMMENTS

    Skin cancer with hydrochlorothiazide … is xipamide (e.g. XIPAGAMMA) an alternative?
    free

    e a-t ON THE INTERNET

    Breast cancer: multigene test ONCOTYPE DX for therapeutic decision making (long version)

    CAR-T cells against cancer? (long version)

    Valsartan preparations with and without nitrosamine contamination

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles